Source comparison
TB-500 vs BPC-157 vs Growth Hormone — Recovery Peptide Comparison
TB-500 Actin upregulation, cell migration Tendons, ligaments, fascia 2–5mg twice weekly (loading), then weekly Strong. Promotes VEGF expression and capillary density Moderate. Inhibits NF-kB pathway, reduces IL-6 and TNF-alpha Best for systemic connective tiss
This comparison does not assign a generated winner or score.
- TB-500
- Actin upregulation, cell migration
- Tendons, ligaments, fascia
- 2–5mg twice weekly (loading), then weekly
- Strong. Promotes VEGF expression and capillary density
- Moderate. Inhibits NF-kB pathway, reduces IL-6 and TNF-alpha
- Best for systemic connective tissue repair and chronic tendinopathy. Works through structural protein pathways rather than growth factor signaling
- BPC-157
- VEGF promotion, fibroblast proliferation
- Gastric mucosa, tendons, muscle
- 250–500mcg daily (localized or systemic)
- Moderate. Accelerates existing angiogenic pathways
- Strong. Nitric oxide modulation, reduced oxidative stress
- Faster-acting for acute injury but less evidence for long-term structural remodelling compared to TB-500
- Growth Hormone (GH)
- IGF-1 amplification, protein synthesis
- Muscle, bone, systemic metabolism
- 2–4 IU daily (research context)
- Indirect. IGF-1 promotes tissue growth broadly
- Minimal direct effect. Systemic metabolic modulator
- Promotes muscle hypertrophy and systemic recovery but doesn't specifically target connective tissue repair pathways like TB-500
- TB-500 and BPC-157 are often stacked by powerlifters researching tb-500 because they work through complementary mechanisms. TB-500 handles structural protein assembly and long-term angiogenesis, while BPC-157 accelerates acute healing through nitric oxide and fibroblast activity. Growth hormone is a different category entirely. It amplifies overall anabolism but doesn't provide the targeted connective tissue benefit that makes TB-500 relevant for athletes dealing with chronic tendon inflammation.